Vitro Diagnostics (VODG) 0.1700 $VODG
Efficacy of Stem Cell Therapy for Stroke Demonstrated in Landmark Study using Vitro Biopharma Stem Cells & Media
ACCESSWIRE - Tue Sep 09, 8:37AM CDT
Golden, CO / ACCESSWIRE / September 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the publication of a research study using its stem cells to treat an animal model of stroke. University of Illinois College of Medicine at Peoria (UICOMP) researchers, led by Dr. Krishna Kumar Veeravalli recently published a study showing a prominent reduction in brain damage by treatment of an animal model of ischemic stroke with human MSCs obtained from Vitro Biopharma through its distributor Neuromics, Inc. The study focused on several measures of brain damage by apoptosis, or programmed cell death that resulted from occlusion of the rat carotid artery, an animal stroke model. Death of brain cells leads to paralysis, loss of function, cognitive impairment, and other effects following a stroke. Hence, reversal of cell death can reverse several adverse neurological effects of stroke. Following the intravenous injection of 250,000 or 1,000,000 Vitro Biopharma's human umbilical cord blood-derived MSCs, there was a dramatic and statistically significant reduction of cellular apoptosis compared to untreated groups. The endpoints included DNA damage and expression levels of numerous genes known to be associated with apoptosis. (Neurochem Res 39: 1511-1521, 2014).
Vitro Biopharma Appoints Jeff Liter to its Board of Directors
ACCESSWIRE - Wed Aug 20, 11:15AM CDT
Golden, CO / ACCESSWIRE / August 20, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma is pleased to announce the appointment of Mr. Jeff Liter to its Board of Directors. Mr. Liter is a versatile business executive who has consistently delivered profitable revenue growth across multiple businesses, industries and geographic regions. He presently serves as the Chief Operating Officer of Progenitor Cell Therapy (PCT), a division of NeoStem a stem cell firm traded on the New York Stock Exchange. His impressive accomplishments include leading 10 M & A transactions from $4M to $2.6B in their entirety. It is anticipated that Mr. Liter will accelerate the rapid growth that Vitro Biopharma is now experiencing, especially in enhanced strategic focus, finance, M&A and other growth initiatives as well.
Vitro Biopharma Announces Strong Third Quarter Revenue & Positioning for Further Growth
ACCESSWIRE - Tue Aug 12, 8:32AM CDT
Golden, Colorado / ACCESSWIRE / August 12, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced continued revenue growth in its third fiscal quarter of 2014 and developments to further increase revenue. Total revenues increased over four-fold in the first nine months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract research services.
Frost & Sullivan Honors Vitro Biopharma for its Outstanding Technological Innovations and Business Strategy in the Stem Cell Tools Industry
PR Newswire Europe - Tue Aug 05, 7:46AM CDT
--The company aims to increase the market penetration of its proprietary MSC-based research products, while expanding its stem cell segment to include differentiated cells derived from MSCs
Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America
ACCESSWIRE - Wed Jul 09, 11:00AM CDT
Golden, CO / ACCESSWIRE / July 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies' commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.
Vitro Biopharma Products Advance Pancreatic Cancer Research
ACCESSWIRE - Tue Mar 11, 9:08AM CDT
Golden, Colorado / ACCESSWIRE / March 11, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches. Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is resistant to conventional therapies. It has recently become apparent that cancer tumor cells are closely associated with other cells called cancer associated fibroblasts or CAFs. These cells promote the malignant process and block immune surveillance. CAFs are thus new drug targets for pancreatic and other cancer therapies. Vitro Biopharma products were used in recent research regarding pancreatic stellate cells, a CAF that is gaining considerable interest for new treatment options through advanced understanding of cancer biology.
10-K: VITRO DIAGNOSTICS INC
Edgar Online - Wed Feb 12, 3:26PM CST
ITEM 7.
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
ACCESSWIRE - Tue Feb 11, 9:19AM CST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.
Vitro Biopharma Expands its Product Lines While Targeting New Stem Cell Markets
ACCESSWIRE - Tue Sep 10, 7:00AM CDT
Golden, Colorado - (ACCESSWIRE - September 10, 2013) - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its current product lines and product development in additional market segments including drug discovery & development together with select opportunities within regenerative medicine market sectors. Vitro's present products target markets within stem cell and cancer research. We provide basic research tools including cell lines, cell culture media and assays of cellular function. We have recently added cancer-associated fibroblast cell lines and novel cell culture media formulations broadening our product offerings for research. Cancer-associated fibroblasts (CAFs) are non-tumor cells within cancerous tumors that promote tumor growth and metastasis.
OTC Daily Alert Stock Watch - Vitro Diagnostics, Inc. (OTCQB: VODG)
WorldStockWire - Thu Aug 29, 3:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vitro Biopharma Appoints Established Life Science Sales Executive to Its Board of Directors
GlobeNewswire - Wed Feb 20, 12:25PM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors. Mr. Shuster is a seasoned and experienced sales executive. He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma. Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003. Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.
Vitro Biopharma Inc announces commercial availability of MSC-derived human osteoblasts, leading to faster recovery of bone fractures
M2 - Wed Jan 23, 10:44AM CST
Stem cell company Vitro Diagnostics Inc (OTCQB:VODG) said on Tuesday that it has introduced a series of osteoblasts products to accelerate bone growth, fracture healing and development of new osteoporosis drugs.
Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth
GlobeNewswire - Tue Jan 22, 8:51AM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging proced
Efficacy of Stem Cell Therapy for Stroke Demonstrated in Landmark Study using Vitro Biopharma Stem Cells & Media
ACCESSWIRE - Tue Sep 09, 8:37AM CDT
Golden, CO / ACCESSWIRE / September 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma announced the publication of a research study using its stem cells to treat an animal model of stroke. University of Illinois College of Medicine at Peoria (UICOMP) researchers, led by Dr. Krishna Kumar Veeravalli recently published a study showing a prominent reduction in brain damage by treatment of an animal model of ischemic stroke with human MSCs obtained from Vitro Biopharma through its distributor Neuromics, Inc. The study focused on several measures of brain damage by apoptosis, or programmed cell death that resulted from occlusion of the rat carotid artery, an animal stroke model. Death of brain cells leads to paralysis, loss of function, cognitive impairment, and other effects following a stroke. Hence, reversal of cell death can reverse several adverse neurological effects of stroke. Following the intravenous injection of 250,000 or 1,000,000 Vitro Biopharma's human umbilical cord blood-derived MSCs, there was a dramatic and statistically significant reduction of cellular apoptosis compared to untreated groups. The endpoints included DNA damage and expression levels of numerous genes known to be associated with apoptosis. (Neurochem Res 39: 1511-1521, 2014).
Vitro Biopharma Appoints Jeff Liter to its Board of Directors
ACCESSWIRE - Wed Aug 20, 11:15AM CDT
Golden, CO / ACCESSWIRE / August 20, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma is pleased to announce the appointment of Mr. Jeff Liter to its Board of Directors. Mr. Liter is a versatile business executive who has consistently delivered profitable revenue growth across multiple businesses, industries and geographic regions. He presently serves as the Chief Operating Officer of Progenitor Cell Therapy (PCT), a division of NeoStem a stem cell firm traded on the New York Stock Exchange. His impressive accomplishments include leading 10 M & A transactions from $4M to $2.6B in their entirety. It is anticipated that Mr. Liter will accelerate the rapid growth that Vitro Biopharma is now experiencing, especially in enhanced strategic focus, finance, M&A and other growth initiatives as well.
Vitro Biopharma Announces Strong Third Quarter Revenue & Positioning for Further Growth
ACCESSWIRE - Tue Aug 12, 8:32AM CDT
Golden, Colorado / ACCESSWIRE / August 12, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced continued revenue growth in its third fiscal quarter of 2014 and developments to further increase revenue. Total revenues increased over four-fold in the first nine months of 2014 compared to the same period in 2013 from increased product sales and revenues from contract research services.
Frost & Sullivan Honors Vitro Biopharma for its Outstanding Technological Innovations and Business Strategy in the Stem Cell Tools Industry
PR Newswire Europe - Tue Aug 05, 7:46AM CDT
--The company aims to increase the market penetration of its proprietary MSC-based research products, while expanding its stem cell segment to include differentiated cells derived from MSCs
Vitro Biopharma Receives Frost & Sullivan Technology Innovation Leadership Award: 2014 Best Practices for Stem Cell Tools & Technology in North America
ACCESSWIRE - Wed Jul 09, 11:00AM CDT
Golden, CO / ACCESSWIRE / July 9, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, is pleased to announce receipt of a prestigious award from Frost & Sullivan. The award is based on independent analysis of competing companies' commitment to innovation, commercial success, application diversity and fulfillment of unmet needs. Vitro Biopharma out-ranked competing firms in all areas evaluated.
Vitro Biopharma Products Advance Pancreatic Cancer Research
ACCESSWIRE - Tue Mar 11, 9:08AM CDT
Golden, Colorado / ACCESSWIRE / March 11, 2014 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that some of its products are being utilized in advancing pancreatic cancer research including development of new diagnostic tests and new therapeutic approaches. Pancreatic cancer remains one of the most deadly and least survivable cancers; it is asymptomatic until quite advanced and is resistant to conventional therapies. It has recently become apparent that cancer tumor cells are closely associated with other cells called cancer associated fibroblasts or CAFs. These cells promote the malignant process and block immune surveillance. CAFs are thus new drug targets for pancreatic and other cancer therapies. Vitro Biopharma products were used in recent research regarding pancreatic stellate cells, a CAF that is gaining considerable interest for new treatment options through advanced understanding of cancer biology.
10-K: VITRO DIAGNOSTICS INC
Edgar Online - Wed Feb 12, 3:26PM CST
ITEM 7.
Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit
ACCESSWIRE - Tue Feb 11, 9:19AM CST
Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.
Vitro Biopharma Expands its Product Lines While Targeting New Stem Cell Markets
ACCESSWIRE - Tue Sep 10, 7:00AM CDT
Golden, Colorado - (ACCESSWIRE - September 10, 2013) - Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro Biopharma, announced expansion of its current product lines and product development in additional market segments including drug discovery & development together with select opportunities within regenerative medicine market sectors. Vitro's present products target markets within stem cell and cancer research. We provide basic research tools including cell lines, cell culture media and assays of cellular function. We have recently added cancer-associated fibroblast cell lines and novel cell culture media formulations broadening our product offerings for research. Cancer-associated fibroblasts (CAFs) are non-tumor cells within cancerous tumors that promote tumor growth and metastasis.
OTC Daily Alert Stock Watch - Vitro Diagnostics, Inc. (OTCQB: VODG)
WorldStockWire - Thu Aug 29, 3:00PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Vitro Biopharma Appoints Established Life Science Sales Executive to Its Board of Directors
GlobeNewswire - Wed Feb 20, 12:25PM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, simultaneously accepted the resignation of Mr. Erik Van Horn from its Board of Directors and appointed Pete Shuster, the CEO of Neuromics, Inc. to its Board of Directors. Mr. Shuster is a seasoned and experienced sales executive. He is the current owner of Neuromics, Inc., a privately held and profitable business focused on sales of numerous (>2500) specialty life science products including stem cell products manufactured by Vitro Biopharma. Neuromics, Inc. sales have grown over 5.5-fold since inception in 2003. Shuster has extensive prior experience in managing sales of computer software and related products for companies including Caterpillar, Baxter Healthcare and Harley-Davidson.
Vitro Biopharma Inc announces commercial availability of MSC-derived human osteoblasts, leading to faster recovery of bone fractures
M2 - Wed Jan 23, 10:44AM CST
Stem cell company Vitro Diagnostics Inc (OTCQB:VODG) said on Tuesday that it has introduced a series of osteoblasts products to accelerate bone growth, fracture healing and development of new osteoporosis drugs.
Vitro Biopharma Launches New Stem Cell Products to Accelerate Bone Growth
GlobeNewswire - Tue Jan 22, 8:51AM CST
Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced the launch of a series of products with application to accelerated bone growth, fracture healing and development of new osteoporosis drugs. The new products are osteoblasts derived from human adult stem cells known as mesenchymal stem cells (MSCs). These cells lead to bone growth and function to maintain bone density and in the recovery from bone fractures. Osteoporosis, a disease characterized by reduction in bone density is thought to result from decreased osteoblast production by MSCs; bone growth necessary for repair of bone fractures also depends on osteoblasts. The new products include native and labeled MSC-derived human osteoblasts in various formats including fluorescent and magnetic cells for use in different imaging methods. For example, magnetic osteoblast cells labeled with super paramagnetic iron oxide (SPIO) may be used for in-vivo imaging of osteoblasts using magnetic resonance imaging (MRI) a common clinical imaging proced
